| P50 | author | Stephen J. Russell | Q53843820 |
| | Shaji K Kumar | Q85960198 |
| | Sikander Ailawadhi | Q87584539 |
| | Wilson I Gonsalves | Q88037405 |
| | Rahma Warsame | Q88368934 |
| | Francis K Buadi | Q88774336 |
| | Taxiarchis Kourelis | Q89499431 |
| | Vivek Roy | Q90151377 |
| | Taimur Sher | Q90151380 |
| | Jeremy T Larsen | Q91113869 |
| | Craig B Reeder | Q94562059 |
| | Prashant Kapoor | Q98668791 |
| | John A. Lust | Q110810892 |
| | Miriam A Hobbs | Q110822873 |
| | P A Amie Fonder | Q114300378 |
| | Asher A Chanan Khan | Q114300389 |
| | P Leif Bergsagel | Q114300391 |
| | Stephen R Zeldenrust | Q114300403 |
| | Ronald S Go | Q56990716 |
| | Eli Muchtar | Q57021390 |
| | Morie A Gertz | Q57052163 |
| | William Hogan | Q59001382 |
| | S. Vincent Rajkumar | Q61123608 |
| | David Dingli | Q66385573 |
| | Robert A Kyle | Q66385695 |
| | Martha Q Lacy | Q66419394 |
| | Angela Dispenzieri | Q37838558 |
| | Nelson Leung | Q42692816 |
| P2093 | author name string | Rafael Fonseca | |
| | A Keith Stewart | |
| | Yi Lin | |
| | Yi L Hwa | |
| | Susan R Hayman | |
| | Angela A Mayo | |
| P2860 | cites work | Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. | Q51518039 |
| | Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. | Q51680781 |
| | Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. | Q51705517 |
| | The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma. | Q51753186 |
| | Analysis of Clinical Factors and Outcomes Associated with Non-Utilization of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant Eligible Patients with Multiple Myeloma. | Q52588018 |
| | Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. | Q52795444 |
| | Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. | Q52860687 |
| | Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. | Q52875785 |
| | Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. | Q53127020 |
| | Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation | Q84013608 |
| | Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy | Q84261808 |
| | Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation | Q84316987 |
| | Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma | Q85552314 |
| | First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies | Q24197999 |
| | High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis | Q24670135 |
| | Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma | Q30301228 |
| | Older patients with myeloma derive similar benefit from autologous transplantation. | Q30370038 |
| | Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma | Q30409713 |
| | Salvage second hematopoietic cell transplantation in myeloma | Q30416452 |
| | Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou | Q33340726 |
| | Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study | Q33387332 |
| | High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l | Q33416028 |
| | High-dose melphalan with autologous bone marrow transplantation for multiple myeloma | Q33453035 |
| | Durable remission with salvage second autotransplants in patients with multiple myeloma | Q33685400 |
| | How we manage autologous stem cell transplantation for patients with multiple myeloma | Q34019581 |
| | High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 |
| | Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. | Q34255145 |
| | Lenalidomide after stem-cell transplantation for multiple myeloma | Q34273726 |
| | Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma | Q35157385 |
| | Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis | Q35172500 |
| | Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years | Q35410550 |
| | Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma | Q35651684 |
| | Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. | Q35685454 |
| | Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease | Q35944707 |
| | Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. | Q35994520 |
| | Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 |
| | A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial | Q36654092 |
| | High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials | Q36714825 |
| | Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. | Q51369301 |
| | Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. | Q51385709 |
| | Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma | Q56970451 |
| | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma | Q56981141 |
| | Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study | Q56995088 |
| | High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial | Q57780128 |
| | Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 |
| | Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial | Q59650507 |
| | High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma | Q68180035 |
| | A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 |
| | Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome | Q71611831 |
| | Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma | Q72240664 |
| | High-dose intravenous melphalan for plasma-cell leukaemia and myeloma | Q72562480 |
| | Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM | Q73330861 |
| | Total therapy with tandem transplants for newly diagnosed multiple myeloma | Q77720623 |
| | Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan | Q79687142 |
| | Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma | Q79696686 |
| | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 |
| | Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial | Q80557088 |
| | Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma | Q80764931 |
| | A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma | Q81606574 |
| | The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis | Q82160201 |
| | Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival | Q82405163 |
| | Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 |
| | Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial | Q36725446 |
| | Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma | Q36765107 |
| | Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation | Q36834629 |
| | Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial | Q36907828 |
| | Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma | Q37162610 |
| | Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols | Q37306614 |
| | Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis | Q37367737 |
| | Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma | Q37375819 |
| | Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines | Q37454445 |
| | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens | Q37533983 |
| | Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation | Q37627044 |
| | Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma | Q37651875 |
| | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. | Q37724272 |
| | Posttransplant maintenance therapy in multiple myeloma: the changing landscape | Q37737800 |
| | Relapsed multiple myeloma: who benefits from salvage autografts? | Q38023515 |
| | Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment | Q38042273 |
| | Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. | Q38094334 |
| | Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations | Q38154080 |
| | Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations | Q38190793 |
| | Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. | Q38650700 |
| | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis | Q38662385 |
| | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. | Q38852886 |
| | Second primary malignancies in multiple myeloma: an overview and IMWG consensus | Q39013620 |
| | Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial | Q39065872 |
| | Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. | Q39070193 |
| | Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy | Q39177792 |
| | Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis | Q39386287 |
| | Autologous stem cell transplant for multiple myeloma patients 70 years or older | Q39633772 |
| | Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival | Q39763521 |
| | International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment | Q39920948 |
| | Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma | Q40201943 |
| | Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide | Q40349501 |
| | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial | Q40899348 |
| | Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma | Q41113942 |
| | Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure | Q41714892 |
| | Autologous transplantation and maintenance therapy in multiple myeloma | Q41756278 |
| | Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement | Q42163250 |
| | A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma | Q43251148 |
| | High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. | Q43573096 |
| | Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 |
| | Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma | Q44044770 |
| | The role of second autografts in the management of myeloma at first relapse. | Q44204181 |
| | Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma | Q44208130 |
| | Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation | Q44385832 |
| | Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 |
| | Second auto-SCT for treatment of relapsed multiple myeloma | Q44758991 |
| | Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability | Q44835439 |
| | Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. | Q45067612 |
| | Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. | Q45361447 |
| | Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide | Q45892382 |
| | Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. | Q45918038 |
| | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Q46052750 |
| | High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study | Q46648237 |
| | High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe | Q46795068 |
| | Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 |
| | Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 |
| | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. | Q47196540 |
| | Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis | Q47207279 |
| | Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. | Q47581210 |
| | High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy | Q47631771 |
| | From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives | Q47794767 |
| | Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? | Q48011772 |
| | Current status of art mobilization in Myeloma | Q48590297 |
| | Chemo-Mobilization in Myeloma-Diminishing Returns in the Era of Novel Agent Induction? | Q49614331 |
| | Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma | Q50058608 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | hematopoietic stem cell transplantation | Q1128050 |
| | stem cell transplantation | Q65592366 |
| P304 | page(s) | 353-367 | |
| P577 | publication date | 2018-07-09 | |
| | 2019-03-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. | |
| P478 | volume | 54 | |